Marijuana Could Be Stealing Sales From This $200 Billion Industry, New Report Shows

This post was originally published on this site

You’d struggle to find an industry with faster growth potential than marijuana, which generated an estimated $5.4 billion in legal sales during 2015. Cannabis research firm ArcView projects the industry could grow at approximately 30% per year through 2020. If this were to happen, legal marijuana sales would be knocking on the door of $22 billion in annual sales by 2020.

It’s not hard to see why marijuana is expanding so quickly, either, with public opinion on the drug rapidly shifting over the past two decades. Following California’s medical marijuana approval in 1996, Gallup found that just a quarter of the American population approved the idea of legalizing marijuana nationally. By 2015, the number of respondents who want to see cannabis legalized nationally has jumped to an all-time high of 58%.

Of course, the marijuana industry is still disadvantaged in a variety of ways. For starters, cannabis remains a schedule 1 drug, meaning it’s considered illegal at the federal level and has no perceived medical benefits. A recent ruling from the U.S. Drug Enforcement Agency backed up that finding.

Because of its scheduling, marijuana businesses have minimal access to basic banking services since many financial institutions fear federal prosecution at a later date. Most marijuana businesses are paying tax on their gross profits instead of net profits since normal business deductions are disallowed in instances where the primary product being sold is federally illicit.

Yet in spite of its many challenges, marijuana’s expansion continues. Half of all U.S. states have legalized medical marijuana, four (along with Washington, D.C.) have legalized recreational marijuana, and residents in nine states will be going to the polls next month to decide if marijuana initiatives or amendments in their state will become law.

This is great news if you support the expansion of marijuana, but it’s not such great news if you’re an employee or investor in the $200 billion alcohol industry.

Should the alcohol industry be worried about cannabis?

According to a 110-page report released by Cowen and Co. senior analyst Vivien Azer earlier this month, entitled “The Cannabis Compendium: Cross-Sector Views on a Budding Industry,” cannabis could begin chipping away at alcohol sales in the United States.

For the time being, the marijuana industry is still in its infancy. For instance, tax revenue generated from legal marijuana sales totaled just $2 million in Washington state in 2014, but jumped to $65 million in 2015. Comparatively, alcohol tax revenue in Washington rose from just $30 million in 2014 to $31 million in 2015. Admittedly, two completely different tax structures and rates are being compared here, but the point is that alcohol sales growth could be slowing or suffering as a direct result of marijuana’s rapid growth.

Azer notes in the report, “Over the last decade, while we have seen a rise in drinkers who use cannabis, we have also seen declines in cannabis users who drink.” In other words, we could continue to see this trade-off of consumers putting down the bottle in favor of picking up pot.

Just how much could the legal marijuana industry be worth? According to Cowen & Co.’s report, the legal marijuana market is currently generating about $6 billion in legal sales with 8 million daily users and 32 million adults who’ve admitted to using cannabis. Cowen analysts believe there’s another $25 billion in annual sales from the underground black market. Once black market sales transition into legal sales, and as more states legalize marijuana, Cowen anticipates the legal marijuana market could grow to $50 billion by 2026. That’s a compound annual growth rate of nearly 24% over the next decade.

Big Tobacco could play a key role

Azer also believes that Big Tobacco companies could benefit from the rapid ascension of the cannabis industry, which is contrary to popular opinion that tobacco sales could suffer if marijuana were to become legal nationally.

It’s no secret that Big Tobacco is struggling, especially in the United States. Tougher smoking laws and an ongoing campaign by the Centers for Disease Control and Prevention to get adults off of smoking tobacco has pushed U.S. smoking rates from more than 40% in the mid-1960s to just 16.8% of adults in 2014. The only solace for Big Tobacco companies like Altria (NYSE:MO) and Reynolds American (NYSE:RAI) has been the addictive nature of nicotine, which has allowed for big price increases to make up for declining cigarette volume.

Big Tobacco has been looking for alternatives to supplement its growth, and marijuana could be the answer. Azer notes that vaping has become quite popular for both nicotine and cannabis, which could provide Big Tobacco a way to infiltrate the marijuana industry, assuming an eventual federal legalization of the drug. By 2036, Azer and her team of analysts believe Big Tobacco (i.e., Altria and Reynolds American) could have 20% market share in the U.S. cannabis industry.

It’s worth noting that in Colorado, arguably the best example of the successes of legalized marijuana in its early stages, a few big cannabis players purchased a majority of the business licenses available. Combined with an extended moratorium on new license issuances, this has allowed the industry to be concentrated in the hands of a much smaller group of marijuana businesses than initially expected. It would appear that cannabis is already leaning in favor of big business, making it seem even more plausible that Big Tobacco could enter the picture.

Marijuana still isn’t investment-worthy

Despite Azer’s rosy forecast, betting your hard-earned money on marijuana stocks is probably not the smartest move at this point.

A lot of Azer’s figures count on the federal government’s legalizing marijuana, which the DEA profoundly rejected in August. It takes a considerable amount of time for petitions to make their way to the DEA for reconsideration, so you can pretty much count on the DEA standing firm on its ruling for at least the next couple of years. This should keep those aforementioned industry disadvantages for cannabis businesses firmly in place for the foreseeable future.

Another big issue for investors is transparency. The vast majority of marijuana stocks aren’t listed on reputable exchanges, meaning obtaining accurate financial information can be difficult. Furthermore, most cannabis companies are losing money and will likely continue to do so until federal laws change. This creates an ongoing funding concern for a number of these businesses.

Until the federal government changes its tune and transparency improves at the investor level, marijuana looks to be an off-limits investment — despite its rapid growth.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Be Sociable, Share!

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.